Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Prostate Cancer Market 

5.1. COVID-19 Landscape: Prostate Cancer Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Prostate Cancer Market, By Drug Class

8.1. Prostate Cancer Market Revenue and Volume, by Drug Class, 2023-2032

8.1.1. Hormonal ADT

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. AR-Directed Therapies

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Cytotoxic agents

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Bone metastases

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. therapeutic vaccines

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. PARP inhibitors

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

8.1.7. Kinase inhibitors

8.1.7.1. Market Revenue and Volume Forecast (2020-2032)

8.1.8. PSMA-targeted radioligands

8.1.8.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Prostate Cancer Market, By Distribution Channel

9.1. Prostate Cancer Market Revenue and Volume, by Distribution Channel, 2023-2032

9.1.1. Hospital Pharmacies

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Drug store & Retail pharmacies

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Online pharmacies

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Prostate Cancer Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2020-2032)

10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

Chapter 11. Company Profiles

11.1. AbbVie, Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Astellas Pharma, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. AstraZeneca p

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Bayer AG

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Clovis Oncology, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Dendreon Pharmaceuticals LLC

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Ferring Pharmaceuticals

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Johnson & Johnson (Janssen)

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Merck & Co., Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Pfizer, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms